Volume 51, Number 12
December 2022

The oral antiviral agents nirmatrelvir-ritonavir (NMV/r) and molnupiravir are used to treat mild-to-moderate COVID-19 infection in outpatients. However, drug-drug interactions (DDIs) with frequently prescribed medications call for extra precaution, especially with the emergence of COVID-19 variants and widespread use of oral COVID-19 treatments.

This latest comprehensive review of available data on DDIs between NMV/r, molnupiravir and common dermatological medications summarises the potential side effects, and suggests strategies for safe COVID-19 treatment. NMV/r has significant DDIs with many common dermatological medications, which may require temporary discontinuation, dosage adjustment, or substitution with other anti-COVID-19 agents such as molnupiravir.

Illustration by Xinyu Li

Idiopathic inflammatory myopathies: Not nearly the end of the road

The clinical spectrum of idiopathic inflammatory myopathies (IIM) has broadened over the past half century from a simple disease characterised primarily by muscle and...

Pharmacokinetic and pharmacogenomic considerations in managing use of nirmatrelvir-ritonavir and molnupiravir and dermatological treatments

The COVID-19 pandemic has been unprecedented in its impact on global health, economic, financial, psychosocial and political systems. The World Health Organization estimates approximately...

Characteristics of anti-transcriptional intermediary factor 1 gamma autoantibody-positive dermatomyositis patients in Singapore

Idiopathic inflammatory myopathies (IIMs) are a heterogeneous group of acquired, systemic autoimmune conditions characterised by muscular and extramuscular manifestations. As a subset within the...

Low skeletal muscle mass predicts poor prognosis of elderly patients after emergency laparotomy: A single Asian institution experience

Emergency laparotomy (ELAP) for elderly patients is associated with higher mortality and increased postoperative complications compared with those undergoing elective surgery.1-3 Elderly patients, who...

Drug interactions between common dermatological medications and the oral anti-COVID-19 agents nirmatrelvir-ritonavir and molnupiravir

In December 2021, an Emergency Use Authorisation was issued by the U.S. Food and Drug Administration (FDA) for the use of the orally active...

MOST CITED ARTICLES

Review on Epidemic of Obesity

Rationale for Redefining Obesity in Asians

MOST VIEWED ARTICLES